Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
PFE-linked ViiV Healthcare reported final 48-week LATITUDE results showing long-acting injectable cabotegravir + rilpivirine cut cumulative regimen-failure risk nearly in half versus daily oral ART (22.8% vs 41.2%).
VF rates were 6.8% vs 28.2%; treatment-related failure 8.9% vs 28.1%; safety profiles were similar, with injection-site reactions most common.
ViiV Healthcare (PFE) will present clinical and real-world data at CROI 2026 highlighting ultra long‑acting (ULA) HIV candidates and established long‑acting therapies.
Key items include first‑in‑human VH184 long‑acting formulation data, 12‑month maintenance results for lotivibart (N6LS)+cabotegravir LA, VH499 capsid inhibitor dosing analyses, and expanded Cabenuva and CAB LA prevention evidence.
Pfizer (NYSE: PFE) reported that the BREAKWATER trial Cohort 3 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI versus FOLFIRI ± bevacizumab in untreated BRAF V600E metastatic colorectal cancer.
Overall survival also showed clinically meaningful prolonged improvement; objective response rate was positive and presented at ASCO GI 2026. Safety was consistent with known profiles and no new signals were identified. The regimen remains investigational and will be submitted to FDA to support potential approval.
PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.
Pfizer (NYSE: PFE) announced the FDA has accepted and granted Priority Review for the supplemental BLA for HYMPAVZI (marstacimab) to expand use to patients ≥6 years with hemophilia A or B with inhibitors and children 6–11 years without inhibitors.
The FDA set a PDUFA action date in Q2 2026 and previously granted Breakthrough Therapy for prophylaxis in pediatric hemophilia B. Submissions rely on Phase 3 BASIS and BASIS KIDS trial data.
Pfizer (NYSE: PFE) launched a cost-savings program on TrumpRx on February 6, 2026, offering discounts on more than 30 branded medicines across women’s health, migraine, arthritis, rare disease and more. The program offers savings up to 85% and averages 50% off list prices for many primary care and select specialty treatments.
Pfizer says the initiative, part of a voluntary Most Favored Nation agreement with the U.S. government, aims to make medicines more affordable for millions—affecting conditions impacting over 100 million patients—and includes a partnership with GoodRx and expansion of PfizerForAll.
Pfizer (NYSE: PFE) reported full-year 2025 revenues of $62.6B, reported diluted EPS of $1.36 and adjusted diluted EPS of $3.22. Fourth-quarter 2025 revenues were $17.6B with adjusted EPS of $0.66. The company reaffirmed full-year 2026 guidance: revenues $59.5–$62.5B and adjusted EPS $2.80–$3.00, expecting ~$5B COVID product revenue and ~20 key pivotal trial starts in 2026.
Notable items include $4.4B intangible-asset impairments in Q4 2025, significant R&D and BD investments, $9.8B dividends returned, and no share repurchases expected in 2026 under current guidance.
Pfizer (NYSE: PFE) reported positive topline Phase 2b VESPER-3 results for PF’3944, an ultra-long-acting injectable GLP-1 RA, showing up to 12.3% placebo-adjusted mean weight loss at week 28 with a monthly maintenance regimen after weekly titration. The primary endpoint was met (P<0.001) across four dose arms.
PF’3944 maintained a tolerable safety profile through week 28; Pfizer plans >20 obesity trials in 2026, including 10 Phase 3 studies for PF’3944 and a planned higher 9.6 mg monthly dose in Phase 3.
Pfizer (NYSE: PFE) reported Cohort 3 results from the BREAKWATER trial evaluating BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI in previously untreated BRAF V600E-mutant metastatic colorectal cancer. The regimen improved confirmed objective response rate to 64.4% versus 39.2% for FOLFIRI with or without bevacizumab (odds ratio 2.76, p=0.001). Estimated median duration of response was not estimable for the investigational arm; 57.4% of responders on the investigational arm had responses ≥6 months. Overall survival was analyzed descriptively (HR 0.49, 95% CI 0.24–1.03; ~10-month follow-up). No new safety signals identified; 8.5% discontinued BRAFTOVI for adverse reactions. Trial completion estimated 2027.
Summary not available.